Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as larotaxel
XRP9881 · 8 trials · 8 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Larotaxel (XRP9881) | EXPERIMENTAL | - |
| 5-Fluorouracil or capecitabine | ACTIVE_COMPARATOR | Each Investigator must choose either IV 5-FU or oral capecitabine regimen before the first participant begins the study and has to consistently use the chosen regimen throughout the study for all participants treated at her/his site. |
| Arm A1 | EXPERIMENTAL | Cohort 1: Her2-ve breast cancer |
| Arm B1 | ACTIVE_COMPARATOR | Cohort 1: Her2-ve breast cancer |
| Arm A2 | EXPERIMENTAL | Cohort 2: Her2+ve breast cancer |
| Arm B2 | ACTIVE_COMPARATOR | Cohort 2: Her2+ve breast cancer |
| Larotaxel + Trastuzumab | EXPERIMENTAL | - |
| larotaxel + Capecitabine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| larotaxel (XRP9881) | DRUG | administered on day 1 as a 1-hour infusion |
| gemcitabine | DRUG | administered on day 1, 8 and 15 as a 30-minute infusion |
| cisplatin | DRUG | 1 hour infusion administered on day 1, 30 minutes after the other treatment |
| 5-Fluorouracil | DRUG | administered as IV infusion from Day 1 to Day 4 |
| Capecitabine | DRUG | administered orally from Day 1 to Day 14 q3w |
| larotaxel (RPR109881, XRP9881) | DRUG | - |
| docetaxel | DRUG | intravenous administration |
| trastuzumab | DRUG | intravenous administration |
| XRP9881 | DRUG | - |
| larotaxel | DRUG | IV infusion on Day 1 of a 21-day cycle |
Inclusion Criteria: * Patients with histology/cytology confirmed Transitional Cell Carcinoma (TCC) with locally advanced (T4b) or metastatic urothelial tract or bladder cancer * ECOG Performance Status 0 or 1 * No prior palliative chemotherapy Exclusion Criteria: * (Neo)Adjuvant chemotherapy if \...
Top 20 of 87 competitors
XRP9881 is an investigational small molecule being studied for the treatment of advanced breast cancer. It is intended for patients whose disease no longer responds to anthracycline, taxane, and capecitabine treatment. The drug is administered intravenously and is currently in clinical development, not yet approved.
XRP9881 is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical research on this investigational oncology drug for the treatment of advanced breast cancer.
XRP9881 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 2 trial has been completed, and the drug remains under investigation for its potential use in advanced breast cancer.
XRP9881 has been studied in one clinical trial with the identifier NCT00087958. This Phase 2 trial was a completed, uncontrolled study that enrolled 168 patients with advanced breast cancer who no longer responded to anthracycline, taxane, and capecitabine treatment. The trial was conducted across multiple countries.
Yes, XRP9881 is also known as RPR109881. The clinical trial NCT00087958, which studied this drug, is titled "Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment." Both names refer to the same investigational drug.